Onconetix faces a critical existential threat as its primary Entadfi product launch has failed to gain traction, evidenced by a 78.9% year-over-year revenue decline in 2026Q1. The company's inability to achieve operating leverage, characterized by a -97.5% ope...
Price trend, volume and key moving averages
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 13, 2026 | -$6.71 vs — | $21,457 vs — |
Q2 2026 Mar 12, 2026 | $12.58 vs — | $303,596 vs — |
Q4 2025 Nov 13, 2025 | -$6.25 vs — | $303,651 vs — |
Q3 2025 Aug 14, 2025 | -$4.05 vs — | $106,494 vs — |
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, announces that its wholly owned subsidiary, Realbotix LLC, has entered into a loan agreement with Onconetix, Inc. (“Onconetix”) for an unsecured bridge loan facility in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on February 12, 2026. The bridge loan provides transa.
Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
Benchmark ONCO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Onconetix, Inc. (ONCO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.74 | $2.67M | -0.16 | -67.7% | -1720.98% | -110.6% | — | |
| $10.93 | $919.11M | -20.62 | — | — | -36.15% | — | |
| $8.33 | $346.88M | -2450.00 | 10.37% | 69.76% | — | — | |
| $33.65 | $6.95B | -12.15 | — | -7585.86% | -69.59% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — | |
| $286.91 | $8B | -21.28 | -100% | — | -34.15% | — |
Onconetix, Inc. (ONCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Onconetix, Inc. (ONCO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 19, 2026·SEC
May 14, 2026·SEC
Get notified when ONCO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Onconetix, Inc. (ONCO) stock FAQ — growth, dividends, profitability & financials explained
Onconetix, Inc. (ONCO) reported $0.6M in revenue for fiscal year 2025.
Onconetix, Inc. (ONCO) saw revenue decline by 67.7% over the past year.
Onconetix, Inc. (ONCO) reported a net loss of $10.2M for fiscal year 2025.
Onconetix, Inc. (ONCO) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.
Onconetix, Inc. (ONCO) had negative free cash flow of $10.3M in fiscal year 2025, likely due to heavy capital investments.
